TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. announced the successful results of its Phase III clinical trial for Denifanstat (ASC40), a first-in-class FASN inhibitor for the treatment of moderate to severe acne vulgaris. The trial met all primary and secondary efficacy endpoints, demonstrating significant improvements in acne symptoms compared to placebo, with a favorable safety profile. The company is in the process of consulting with the China National Medical Products Administration (NMPA) for a New Drug Application (NDA), which could enhance its market positioning in dermatology and potentially benefit stakeholders by expanding its product portfolio.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, cancer, and other unmet medical needs. The company is known for its work in the development of first-in-class and best-in-class drugs, particularly in the field of dermatology and oncology.
Average Trading Volume: 8,566,753
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.67B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.